Researchers randomized 53 patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) to undergo either thrombolysis with 50 mg of recombinant tissue plasminogen activator (rt-PA) or hemodilution within 11 days of symptom onset. They were followed for one year. Among CRVO patients, median BCVA was 20/60 in the rt-PA group vs. 20/400 in the hemodilution group. Among BRVO patients, there was a tendency for better vision in the rt-PA group, but the difference did not reach statistical significance, possibly due to the smaller subject pool. Retina, July/August 2009

Dr Sarbjit Singh
EYE FOR EXCELLENCE

AsianOphthalmology